- Home
- PCQ vs CRBP Comparison
PCQ vs CRBP Comparison
Compare PCQ & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCQ | CRBP |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.1M | 190.3M |
| IPO Year | 2001 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PCQ | CRBP |
|---|---|---|
| Price | $8.21 | $7.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 154.1K | ★ 902.0K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 4.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $8.35 | $7.12 |
| 52 Week High | $9.19 | $20.56 |
Technical Indicators
Market Signals| Indicator | PCQ | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 13.70 | 23.25 |
| Support Level | N/A | N/A |
| Resistance Level | $9.16 | $8.54 |
| Average True Range (ATR) | 0.08 | 0.80 |
| MACD | -0.04 | -0.49 |
| Stochastic Oscillator | 11.43 | 11.28 |
Price Performance
Historical ComparisonAbout PCQ PIMCO California Municipal Income Fund
PIMCO California Municipal Income Fund is a closed-end management investment company. It seeks to provide current income exempt from federal, New York State, and New York City income tax. The fund invests across sectors including healthcare, property, education, Natural Gas, and others.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.